Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patientswmm2022-01-06T05:38:03+00:00January 4th, 2022|2022 Publications, Featured Publications, Publications| Read More
NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLLwmm2022-01-08T23:37:03+00:00December 28th, 2021|2021 Publications, Publications| Read More
Plan for a Successful International Drug Approval with Early Development of the Accompanying CDxwmm2022-01-04T04:43:02+00:00December 8th, 2021|2021 Publications, Publications| Read More
Global Standardization of Flow Cytometry Results with AI Systemswmm2022-01-11T05:29:29+00:00December 8th, 2021|2021 Videos, Featured Videos, Videos, Webinars| Read More
Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune Systemwmm2021-06-24T18:20:34+00:00June 24th, 2021|2021 Press Releases, Press Releases| Read More
Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and Chinawmm2021-06-03T20:36:18+00:00June 3rd, 2021|2021 Press Releases, Press Releases| Read More
Invivoscribe To Present At Biotech Showcase™ 2019 In San Franciscowmm2021-02-26T19:10:54+00:00January 3rd, 2019|2019 Press Releases, Press Releases| Read More
Invivoscribe® Releases LymphoTrack® TRB Assay on MiSeq® and LymphoTrack® Minimal Residual Disease (MRD) Softwarewmm2021-02-26T19:12:40+00:00November 7th, 2017|2017 Press Releases, Press Releases| Read More
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.wmm2021-02-26T19:12:46+00:00August 1st, 2017|2017 Press Releases, Press Releases| Read More
FDA approves new combination treatment for acute myeloid leukemiawmm2021-02-26T19:12:55+00:00April 28th, 2017|2017 Press Releases, Press Releases| Read More
